Opiant Announces Publication of Manuscript Treatment of Overdose in the Synthetic Opioid Era in Peer-Reviewed Journal Pharmacology & Therapeutics
November 02 2021 - 4:05PM
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company
advancing medicines to better treat addictions and drug overdose,
today announced the publication of a manuscript entitled “Treatment
of Overdose in the Synthetic Opioid Era” authored by Phil Skolnick,
PhD, DSc (hon.), Opiant’s Chief Scientific Officer. The paper is
published in the peer-reviewed journal Pharmacology &
Therapeutics and can be viewed at:
https://www.sciencedirect.com/science/article/pii/S0163725821002217?via%3Dihub
The paper includes a literature-based review of overdose and
treatment, as the United States reckons with illicit and high
potency synthetic opioids, such as fentanyl. Over 80% of 69,000
opioid overdose deaths in 2020 were linked to synthetic opioids,
and they are now the most common substances involved across all
drug overdose deaths. The paper also highlights the heavy toll of
non-fatal overdoses. For each opioid-induced fatality, there are
between 6.4-8.4 non-fatal overdoses which can lead to long-term
physical and mental disability.
Roger Crystal, M.D., President and CEO, Opiant, said: “Dr.
Skolnick’s review is an important and timely reminder of the public
health threat from opioid overdose, already the number-one cause of
death for 25-64 year olds, and further heightened in the era of
synthetic opioids such as fentanyl. Synthetic opioids are far more
potent and have a longer duration of action than, for example,
heroin, and have created significant new challenges for the
treatment of overdose. The paper discusses the importance of
developing stronger opioid antagonists to combat this threat.
Opiant is proud to be a leader in this effort.”
About Opiant Pharmaceuticals,
Inc. Opiant Pharmaceuticals, Inc., the company that
developed NARCAN® Nasal Spray, is building a
leading franchise of new medicines to combat addictions
and drug overdose. For more information
visit: www.opiant.com.
Forward-Looking StatementsThis press release
contains forward-looking statements, including statements for
OPNT003’s potential as an opioid overdose reversal agent. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements, and among other things, our ability to
maintain cash balances and successfully commercialize or partner
our product candidates currently under development. In some cases,
you can identify forward-looking statements by terminology such as
"may," "will," "should," "could," "would," "expects," "plans,"
"intends," "anticipates," "believes," "estimates," "predicts,"
"projects," "potential," or "continue" or the negative of such
terms and other comparable terminology. These statements are only
predictions based on our current expectations and projections about
future events. You should not place undue reliance on these
statements. Actual events or results may differ materially. In
evaluating these statements, you should specifically consider
various factors. Additional factors that could materially affect
actual results can be found in our Form 10-K for the year
ended December 31, 2020, filed with the Securities and
Exchange Commission on March 4, 2021, including under the
caption titled "Risk Factors." These and other factors may
cause our actual results to differ materially from any
forward-looking statement. We undertake no obligation to update any
of the forward-looking statements after the date of this press
release to conform those statements to reflect the occurrence of
unanticipated events, except as required by applicable law.
For Media and Investor Inquiries:Ben Atkins, Opiant(310)
598-5410batkins@opiant.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Apr 2023 to Apr 2024